Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  JAMA ophthalmology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaophthalmol.2013.6203PMID 24336915
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.

  2014cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease

  2013cited by this paper
• Role of Intravitreal Inflammatory Cytokines and Angiogenic Factors in Proliferative Diabetic Retinopathy

  2012cited by this paper
• Interleukin-8 (CXCL8) in Tumor Associated Non-Vascular Extracellular Fluids: Its Diagnostic and Prognostic Values. A Review

  2012cited by this paper
• Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study.

  2012cited by this paper
• Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines.

  2012cited by this paper
• Roles of IL-8 in Ocular Inflammations: A Review

  2011cited by this paper
• Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.

  2011cited by this paper
• Vitreous and serum levels of vascular endothelial growth factor and platelet‐derived growth factor and their correlation in patients with non‐proliferative diabetic retinopathy and clinically significant macula oedema

  2011cited by this paper
• Cytokine concentration in aqueous humor of eyes with diabetic macular edema

  2011cited by this paper
• Intraocular oxygen distribution in advanced proliferative diabetic retinopathy.

  2011cited by this paper
• Ocular pharmacokinetics of 0.45% ketorolac tromethamine

  2010cited by this paper
• PRELIMINARY ASSESSMENT OF CELECOXIB AND MICRODIODE PULSE LASER TREATMENT OF DIABETIC MACULAR EDEMA

  2010cited by this paper
• Nonsteroidal anti-inflammatory drugs in ophthalmology.

  2010cited by this paper
• ANGIOGENIC AND INFLAMMATORY MARKERS IN THE INTRAOCULAR FLUID OF EYES WITH DIABETIC MACULAR EDEMA AND INFLUENCE OF THERAPY WITH BEVACIZUMAB

  2010cited by this paper
• The role of PGE2 receptor EP4 in pathologic ocular angiogenesis.

  2009cited by this paper
• Immunological mechanisms in the pathogenesis of diabetic retinopathy

  2008cited by this paper
• Topical Administration of Nepafenac Inhibits Diabetes-Induced Retinal Microvascular Disease and Underlying Abnormalities of Retinal Metabolism and Physiology

  2007cited by this paper
• The effect of long-term treatment with sulindac on the progression of diabetic retinopathy*

  2007cited by this paper
• Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.

  2006cited by this paper
• Prostaglandin E2 Induces Interleukin-8 Gene Transcription by Activating C/EBP Homologous Protein in Human T Lymphocytes*

  2005cited by this paper
• Exogenous superoxide mediates pro-oxidative, proinflammatory, and procoagulatory changes in primary endothelial cell cultures.

  2005cited by this paper
• A central role for inflammation in the pathogenesis of diabetic retinopathy

  2004cited by this paper
• Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.

  2003cited by this paper
• Sources of PDGF expression in murine retina and the effect of short-term diabetes.

  2003cited by this paper
• Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppression

  2002cited by this paper
• Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy.

  2002cited by this paper
• Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists.

  2001cited by this paper
• Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature.

  1999cited by this paper
• Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Cell-associated human retinal pigment epithelium interleukin-8 and monocyte chemotactic protein-1: immunochemical and in-situ hybridization analyses.

  1997cited by this paper
• Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells.

  1994cited by this paper
• Nonsteroidal Anti-inflammatory Drugs in Ophthalmology

  1993cited by this paper
• Effect of Aspirin Alone and Aspirin Plus Dipyridamole in Early Diabetic Retinopathy: A Multicenter Randomized Controlled Clinical Trial

  1989cited by this paper
• Clinical Ophthalmology Dovepress Critical Appraisal of Ophthalmic Ketorolac in Treatment of Pain and Inflammation following Cataract Surgery

  year unknowncited by this paper

• Lights and Shadows of Cytokines in Age‐Related Eye Diseases: A Narrative Literature Review

  2025cites this paper
• INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

  2025influential citation
• Analysis of 24 pro-inflammatory cytokines in aqueous and serum of 94 patients without diabetes

  2025cites this paper
• Analysis of Aqueous Interleukin-6 in Diabetic Retinopathy: A Prospective, Controlled Trial of 328 Eyes.

  2025cites this paper
• Inflammatory Mediators in the Pathophysiology of Diabetic Retinopathy (INSPIRE): Study Design and Baseline Characteristics

  2025influential citation
• Cytokines in age-related eye diseases: pathogenesis and potential targets for innovative therapies

  2025cites this paper
• Retinal microglia-derived S100A9 incite NLRP3 inflammasome in a Western diet fed Ossabaw pig retina

  2024cites this paper
• Rheumatoid arthritis and diabetic retinopathy: A two-sample Mendelian randomization study

  2024cites this paper
• Research progress on the role of PDGF/PDGFR in type 2 diabetes.

  2023cites this paper
• Systemic inflammatory regulators and proliferative diabetic retinopathy: A bidirectional Mendelian randomization study

  2023cites this paper
• Comprehensive assessment of growth factors, inflammatory mediators, and cytokines in vitreous from patients with proliferative diabetic retinopathy.

  2022cites this paper
• The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications

  2022cites this paper
• Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis

  2022cites this paper
• Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients

  2021cites this paper
• Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial

  2021cites this paper
• Inflammatory mediators in diabetic retinopathy: Deriving clinicopathological correlations for potential targeted therapy

  2021cites this paper
• Expression profiles of circRNAs, lncRNAs, and mRNAs in extreme phenotypes of diabetic retinopathy

  2020cites this paper
• Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications.

  2019cites this paper
• The relationship between mean platelet volume and diabetic retinopathy: a systematic review and meta-analysis

  2019cites this paper
• Treatment of exudative age‐related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega‐3: A randomized trial

  2019influential citation
• Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial

  2018cites this paper
• Intravitreal diclofenac versus intravitreal bevacizumab in persistent diabetic macular edema: Anatomical and functional outcome

  2018cites this paper
• Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies

  2018cites this paper
• Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy

  2016cites this paper
• Safety and Feasibility of Quantitative Multiplexed Cytokine Analysis From Office-Based Vitreous Aspiration

  2016cites this paper
• Efficacy and vitreous levels of topical NSAIDs

  2015cites this paper
• Angiogenic and Inflammatory Vitreous Biomarkers Associated With Increasing Levels of Retinal Ischemia.

  2015cites this paper
• Lipid Mediators Are Critical in Resolving Inflammation: A Review of the Emerging Roles of Eicosanoids in Diabetes Mellitus

  2015cites this paper
• Novel Pharmacotherapies in Diabetic Retinopathy

  2015cites this paper
• Novel Approaches for Retinal Drug and Gene Delivery.

  2014cites this paper
• Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy

  2014cites this paper